Amarin CORP Plcuk

Amarin Corporation plc announced its second quarter 2026 financial results, highlighting global volume growth, reduced operating expenses, and positive cash flow driven by its international commercial strategy.

Amarin Corporation plc announced its first quarter 2026 financial results, showing a 7% increase in total net revenue driven by higher international sales and reiterating its expectation for full-year positive cash flow.

Amarin Corporation plc announced a reduction in its Board size and updated its non-employee director compensation policy, following two directors' decisions not to seek re-election.

Amarin Corporation plc reported significantly narrowed losses and achieved positive cash flow in Q4 2025, driven by strategic initiatives and cost efficiencies.

Amarin Corporation plc announced preliminary unaudited 2025 financial highlights, achieving positive cash flow ahead of schedule and outlining strategic priorities for global expansion.

Amarin Corporation plc reported a 17% increase in total net revenue for Q3 2025, alongside a significant reduction in operating and net losses, driven by U.S. sales and cost discipline.

Amarin Corporation plc reported a significant decrease in total revenue for Q2 2026, primarily driven by a substantial drop in licensing and royalty income, alongside a moderate decline in product revenue.

Amarin Corporation plc announced its first quarter 2026 financial results, reporting a 7% increase in total revenue to $45.1 million, driven by growth in international product sales and licensing revenue.

Amarin Corporation plc reported a significantly reduced net loss for Q3 2025, driven by increased U.S. product revenue and strategic European partnership, despite overall nine-month revenue decline.

Amarin Corporation plc reported a significant increase in net loss for the first half of 2025, driven by restructuring costs from a new European licensing agreement with Recordati and continued challenges in the U.S. market due to generic competition.

Amarin Corporation plc reports a net loss of $15.7 million for Q1 2025, with product revenue declining due to generic competition in the U.S.

Amarin Corporation's Q3 2024 results show a decrease in revenue due to generic competition in the U.S., offset by growth in European and international markets.

Amarin Corporation plc reports a 7% decrease in total revenue for 2025, driven by declining U.S. VASCEPA sales amidst generic competition, while advancing international commercialization and restructuring efforts.

Amarin Corporation reports its 2024 financial results, highlighting challenges from U.S. generic competition and progress in European and international markets.

Amarin Corporation plc has appointed Jonathan Provoost as Executive Vice President, Chief Legal and Compliance Officer, and filed its annual report on Form 10-K, detailing its financial performance and strategic initiatives.

Peter L. Fishman, SVP, CFO of Amarin Corp Plcuk, reported multiple transactions in common stock on August 1, 2026.

Peter L. Fishman, SVP, CFO of Amarin Corp Plcuk, reported multiple transactions in common stock on July 1, 2026.

David Paul Keenan, EVP, Chief Operating Officer of Amarin Corp Plcuk, reported multiple transactions in common stock on July 1, 2026.

Steven B Ketchum, EVP, Chief Scientific Officer of Amarin Corp Plcuk, reported multiple transactions in common stock on July 1, 2026.

Jonathan Provoost, EVP, Chief Legal Officer of Amarin Corp Plcuk, reported multiple transactions in common stock on July 1, 2026.

Amarin Corp CEO Aaron Berg reported transactions involving American Depositary Shares and Restricted Stock Units.

Amarin Corporation plc has announced its 2026 Annual General Meeting of Shareholders, scheduled for May 13, 2026, to vote on director re-elections, executive compensation, auditor appointment, and share issuance authorities.

Amarin Corporation PLC outlines its 2024 achievements, including revenue of over $200 million and a strong cash position, while setting strategic priorities for 2025 to unlock the global potential of VASCEPA/VAZKEPA and maximize shareholder value.

Amarin Corporation PLC's upcoming Annual General Meeting on April 18, 2024, will address director re-elections, executive compensation, a stock incentive plan amendment, capital reduction, share repurchase authorization, and board declassification.

Sarissa Capital Management LP and Alexander J Denner have filed an Amendment No. 15 to their Schedule 13D, disclosing that Mark DiPaolo will not seek re-election to Amarin Corporation PLC/UK's board of directors at the 2025 Annual Meeting of Shareholders, while maintaining an 8.08% beneficial ownership stake.